Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18502525 | 1.00 | MEN1 (0.38) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL10058453 | 0.87 | TSHR (0.35) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL7869696 | 0.82 | MEN1 (0.39) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL29394016 | 0.82 | TSHR (0.36) | MEN1KMT2ATSHRTP53TDP1 | |
| SCHEMBL121180 | 0.82 | MEN1 (0.39) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL18295171 | 0.82 | — | — | |
| SCHEMBL21362842 | 0.82 | CYP3A4 (0.42) | TSHR | |
| SCHEMBL961275 | 0.82 | — | — | |
| SCHEMBL5599016 | 0.81 | MEN1 (0.38) | MEN1GAACYP2C9CYP2C19KMT2A | |
| SCHEMBL20798220 | 0.79 | MEN1 (0.37) | MEN1GAACYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318435-B2 | Recombinant protein produced from cholinesterase gene derived from Pseudomonas aeruginosa and the composition comprising the same for treating or preventing a neurological disease | SKYPEACH CO., LTD. (KR) | 2025-06-03 | — | — | US | claimed |
| CN-118114335-A | Building carbon emission prediction method and system based on database platform | 陕西建工控股集团未来城市创新科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-08-31 | — | — | US | claimed |
| EP-4188919-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | Etat Français représenté par la Direction Centrale Du Service de Santé des Armées (FR) | 2023-06-07 | — | — | EP | claimed |
| US-20230026578-A1 | A recombinant protein produced from cholinesterase gene derived from Pseudomonas aeruginosa and the composition comprising the same for treating or preventing a neurological disease | SKYPEACH CO., LTD (KR) | 2023-01-26 | — | — | US | claimed |
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | claimed |
| US-20210041339-A1 | METHODS FOR DETECTION OF THE PERMEATION OF CHEMICAL WARFARE AGENTS THROUGH MEMBRANES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-02-11 | — | — | US | claimed |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| US-10801987-B2 | 2H to 1T phase based transition metal dichalcogenide sensor for optical and electronic detection of strong electron donor chemical vapors | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-10-13 | — | — | US | claimed |
| US-10722743-B2 | Multicatalyst polyelectrolyte membranes and materials and methods utilizing the same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-07-28 | — | — | US | claimed |
| US-20200163952-A1 | COMPOSITIONS AND METHODS FOR TREATING NERVE AGENT EXPOSURE | HOFFMAN STEVEN (US) | 2020-05-28 | — | — | US | claimed |
| US-10421952-B1 | Mutant organophosphorus acid anhydrolase enzymes having increased catalytic efficiency on V-agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2019-09-24 | — | — | US | claimed |
| WO-2019050923-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| US-20180024085-A1 | 2H TO 1T PHASE BASED TRANSITION METAL DICHALCOGENIDE SENSOR FOR OPTICAL AND ELECTRONIC DETECTION OF STRONG ELECTRON DONOR CHEMICAL VAPORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-01-25 | — | — | US | claimed |
| US-20170007871-A1 | Multicatalyst Polyelectrolyte Membranes and Materials and Methods Utilizing the Same | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2017-01-12 | — | — | US | claimed |
| US-20150038588-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-02-05 | — | — | US | claimed |
| EP-2822655-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-01-14 | — | — | EP | claimed |
| WO-2013132490-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-09-12 | — | — | WO | claimed |
| EP-1928560-A2 | ENZYMES AND FORMULATIONS FOR BROAD-SPECIFICITY DECONTAMINATION OF CHEMICAL AND BIOLOGICAL WARFARE AGENTS | Verenium Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2008036061-A2 | ENZYMES AND FORMULATIONS FOR BROAD-SPECIFICITY DECONTAMINATION OF CHEMICAL AND BIOLOGICAL WARFARE AGENTS | VERENIUM CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MEN1 1585/4885GAA 2045/4885CYP2C9 3587/4885 |
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | BCHE, ACHE, CHAT | MEN1 3307/4885GAA 507/4885CYP2C9 101/4885 |
| US-20150038588-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | CHRNA3, GAP43, CHRNA5 | MEN1 3486/4885GAA 2656/4885CYP2C9 858/4885 |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MEN1 1585/4885GAA 2045/4885CYP2C9 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.